PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.14
D/E of 0.14 while TRAW has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
4.63
Similar net debt to TRAW's 4.52. Guy Spier would examine if industry leverage norms make sense for both companies.
-3518.20
Negative coverage while TRAW shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
1.20
Current ratio below 50% of TRAW's 2.48. Jim Chanos would check for potential working capital crisis.
No Data
No Data available this quarter, please select a different quarter.